Vistagen Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period. This is the fiscal third-quarter report for the quarter ended December 31, 2011, covering the three and nine months then ended. VistaGen is a development-stage biotechnology company pursuing stem-cell-based drug rescue and cell therapy programs and developing AV-101 for neuropathic pain. In May 2011, a merger made VistaGen’s business the business of the public company, which adopted the VistaGen name.
Financial performance and position
| Metric | Three months ended Dec. 31 | Nine months ended Dec. 31 |
|---|---|---|
| Revenue | 2011: $2,365; 2010: $584,772 | 2011: $873,269; 2010: $1,718,269 |
| Operating loss | 2011: $2.85 million; 2010: $2.53 million | 2011: $6.26 million; 2010: $3.85 million |
| Net loss | 2011: $4.50 million; 2010: $3.39 million | 2011: $9.17 million; 2010: $5.95 million |
| Net loss per share | 2011: $0.28; 2010: $0.65 | 2011: $0.65; 2010: $1.13 |
| Cash used in operating activities | Nine months 2011: $2.85 million; 2010: $0.75 million |
At December 31, 2011, cash and cash equivalents were $166,421, total assets $399,717, and total liabilities $5.16 million. Current assets of $281,926 were below current liabilities of $2.22 million, implying a working-capital deficit of approximately $1.94 million. Stockholders’ deficit was $4.76 million. The balance sheet also showed approximately $3.55 million of notes payable and accrued interest, plus $29,435 of capital lease obligations. Convertible notes and accrued interest shown at March 31, 2011 had been eliminated by conversion or exchange.
Revenue was negligible in the quarter, including a negative NIH grant adjustment. Gross margin is not meaningful for this development-stage company with minimal revenue and no reported cost-of-revenue line.
Material changes versus prior periods
- Nine-month revenue fell 49% year over year, primarily as AV-101 grant-funded work was rescheduled and the CIRM grant concluded in September 2011.
- Nine-month R&D expense rose to $3.56 million from $1.81 million, reflecting increased AV-101 work, UHN stem-cell research, staffing, and related costs.
- Nine-month G&A declined modestly to $3.57 million from $3.75 million. The prior-year period included $2.12 million of costs for a Toronto Stock Exchange listing that did not proceed; current-period costs included merger and public-company expenses.
- Operating cash use increased to $2.85 million from $0.75 million. Financing provided $2.89 million, leaving cash up only $27,078 over the nine months.
- In December, the company cancelled the $4.0 million Platinum note and related warrants in exchange for Series A preferred stock, recording a $1.19 million loss on early debt extinguishment.
Outlook, risks, and unusual items
- Liquidity and going concern: Management said available cash, including subsequent warrant-exercise proceeds, would not fund operations for the next 12 months. It estimated approximately $7 million of cash expenditures over that period and expected to seek private financing, collaborations, license fees, and grant awards. Failure to obtain funding could require reducing, deferring, or discontinuing R&D and could threaten continued operations.
- Programs: The filing reports that a Phase 1b AV-101 study began in early 2012. Management planned to initiate Phase 2 in the fourth quarter of 2012, subject to additional grant funding and FDA approval. The company reported more than $8.9 million in NIH awards for AV-101 development.
- Commitments: Under an October 2011 UHN research amendment, the company committed to pay $50,000 monthly through September 2012. A related license could require $3.9 million in milestone payments if specified milestones are achieved, plus royalties on attributable revenue.
- Financing and dilution: The company used discounted warrant exercises and preferred-stock exchanges to address financing and liabilities. These transactions generated cash and settled some service obligations but involved warrant repricing, equity issuance, and potential dilution. At December 31, 3.45 million warrants and 4.81 million options were outstanding.
- Other risks and controls: Results remain dependent on financing, grants, clinical and preclinical outcomes, FDA review, and successful development of the company’s technology. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Cash raised after December 31, including warrant proceeds, and the actual remaining cash runway versus the $7 million estimated expenditure need.
- Progress and funding for the AV-101 Phase 1b study and whether the proposed Phase 2 timing and conditions remain achievable.
- Terms, timing, and dilution implications of future financing, including preferred-stock conversion rights and outstanding options and warrants.
- Ability to meet note repayments, UHN monthly research payments, and any milestone or royalty obligations that become due.
- Whether revenue-generating collaborations, grants, or licensing arrangements materialize; the filing reports no sustainable operating revenue.